Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
Dual-action eye drop targeting both evaporative and inflammatory dry eye disease moving to Phase 3
Positive Phase 1b results for ocular surface pain candidate validate TRPV1 antagonist approach and strengthen confidence in ongoing Phase 2 study
Combined potential peak sales exceeding $2 billion assuming successful development and commercialization1
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results.
